These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 15218401)

  • 1. High-density lipoprotein metabolism and progression of atherosclerosis: new insights from the HDL Atherosclerosis Treatment Study.
    Asztalos BF;
    Curr Opin Cardiol; 2004 Jul; 19(4):385-91. PubMed ID: 15218401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection.
    Meyers CD; Kashyap ML
    Curr Opin Cardiol; 2004 Jul; 19(4):366-73. PubMed ID: 15218398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple actions of high-density lipoprotein.
    Florentin M; Liberopoulos EN; Wierzbicki AS; Mikhailidis DP
    Curr Opin Cardiol; 2008 Jul; 23(4):370-8. PubMed ID: 18520722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-density lipoproteins: a therapeutic target for atherosclerotic cardiovascular disease.
    Gomaraschi M; Calabresi L; Franceschini G
    Expert Opin Ther Targets; 2006 Aug; 10(4):561-72. PubMed ID: 16848692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic interventions targeted at the augmentation of reverse cholesterol transport.
    Toth PP; Davidson MH
    Curr Opin Cardiol; 2004 Jul; 19(4):374-9. PubMed ID: 15218399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease.
    Besler C; Heinrich K; Riwanto M; Lüscher TF; Landmesser U
    Curr Pharm Des; 2010 May; 16(13):1480-93. PubMed ID: 20196740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HDL heterogeneity and atherosclerosis.
    Tailleux A; Fruchart JC
    Crit Rev Clin Lab Sci; 1996; 33(3):163-201. PubMed ID: 8828000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances on the antiatherogenic effects of HDL-derived proteins and mimetic peptides.
    Petraki MP; Mantani PT; Tselepis AD
    Curr Pharm Des; 2009; 15(27):3146-66. PubMed ID: 19754388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Therapies Focused on High-Density Lipoproteins Associated with Cardiovascular Disease.
    Estrada-Luna D; Ortiz-Rodriguez MA; Medina-Briseño L; Carreón-Torres E; Izquierdo-Vega JA; Sharma A; Cancino-Díaz JC; Pérez-Méndez O; Belefant-Miller H; Betanzos-Cabrera G
    Molecules; 2018 Oct; 23(11):. PubMed ID: 30360466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of nonstatin lipid drug therapy on high-density lipoprotein metabolism.
    Rader DJ
    Am J Cardiol; 2003 Apr; 91(7A):18E-23E. PubMed ID: 12679199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current understanding of the role of high-density lipoproteins in atherosclerosis and senescence.
    Nofer JR; Walter M; Assmann G
    Expert Rev Cardiovasc Ther; 2005 Nov; 3(6):1071-86. PubMed ID: 16292998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDL and arteriosclerosis: beyond reverse cholesterol transport.
    Nofer JR; Kehrel B; Fobker M; Levkau B; Assmann G; von Eckardstein A
    Atherosclerosis; 2002 Mar; 161(1):1-16. PubMed ID: 11882312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drugs in development: targeting high-density lipoprotein metabolism and reverse cholesterol transport.
    Duffy D; Rader DJ
    Curr Opin Cardiol; 2005 Jul; 20(4):301-6. PubMed ID: 15956827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiatherogenic role of high-density lipoproteins: insights from genetically engineered-mice.
    Escola-Gil JC; Calpe-Berdiel L; Palomer X; Ribas V; Ordonez-Llanos J; Blanco-Vaca F
    Front Biosci; 2006 May; 11():1328-48. PubMed ID: 16368520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological activities of HDL subpopulations and their relevance to cardiovascular disease.
    Camont L; Chapman MJ; Kontush A
    Trends Mol Med; 2011 Oct; 17(10):594-603. PubMed ID: 21839683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport.
    von Eckardstein A; Nofer JR; Assmann G
    Arterioscler Thromb Vasc Biol; 2001 Jan; 21(1):13-27. PubMed ID: 11145929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The paradox of dysfunctional high-density lipoprotein.
    Ansell BJ; Fonarow GC; Fogelman AM
    Curr Opin Lipidol; 2007 Aug; 18(4):427-34. PubMed ID: 17620860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammation, high-density lipoprotein and cardiovascular dysfunction.
    Haas MJ; Mooradian AD
    Curr Opin Infect Dis; 2011 Jun; 24(3):265-72. PubMed ID: 21326098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia.
    Le Goff W; Guerin M; Chapman MJ
    Pharmacol Ther; 2004 Jan; 101(1):17-38. PubMed ID: 14729390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene activation, apolipoprotein A-I/high density lipoprotein, atherosclerosis prevention and longevity.
    Luoma PV
    Pharmacol Toxicol; 1997 Aug; 81(2):57-64. PubMed ID: 9298501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.